Remarkable, Ragab H et al. described that serum sCD163 was augmented in Non-Alcoholic Fatty Liver Disease (NAFLD) cases compared to healthy controls, but it actually showed significantly higher levels in the obese- and non-obese diabetic patients as compared with lean healthy subjects. Here, CD163 is linked to metabolic dysfunction-associated steatotic liver disease.